Researchers have used advanced genetic sequencing on a Brisbane family to identify a gene mutation linked to ulcerative colitis, a type of inflammatory bowel condition, sparking hopes of new ...

Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics ...

Indiana University School of Medicine scientists have uncovered new evidence that an age-related blood condition may ...

Pentasa is an aminosalicylate indicated for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis in adult patients.

MYMICHIGAN HEALTH: March is Colorectal Cancer Awareness Month, a time to talk about prevention, screening, and early ...

Capital strengthens the advancement of EQ504 through key clinical milestonesAnticipated net proceeds, along with existing cash and cash ...

Severe flare-ups are one of the greatest challenges of living with ulcerative colitis (UC). One option to try alongside your usual treatments is a low-residue diet. Its meant to reduce the amount of ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative ...

March 9, Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First ...

For too long, colorectal cancer has carried the unfortunate label of an “older person’s disease.” It’s a perception that is dangerously outdated and, frankly, costing lives. As someone embedded in the ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...